1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Argenx SE
  6. News
  7. Summary
    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
Real-time Euronext Bruxelles  -  08:35 2022-07-06 am EDT
369.20 EUR   +0.30%
06/29US Futures Marginally Higher Ahead of Final Q1 GDP Reading
MT
06/28Stifel Reinstates argenx SE at Buy With $460 Price Target
MT
06/27ARGENX : Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Move Higher in Friday Trading

05/13/2022 | 11:54am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ADAPTIMMUNE THERAPEUTICS PLC 0.61% 1.66 Delayed Quote.-55.73%
AKARI THERAPEUTICS, PLC 1.06% 0.95 Delayed Quote.-36.67%
ARGENX SE 0.30% 369.2 Real-time Quote.16.75%
AVADEL PHARMACEUTICALS PLC 40.08% 3.6 Delayed Quote.-55.45%
DBV TECHNOLOGIES -0.82% 4.582 Real-time Quote.51.03%
GENFIT -0.95% 3.13 Real-time Quote.-26.78%
IDEX BIOMETRICS ASA -5.86% 1.076 Real-time Quote.-63.83%
IDEX CORPORATION 0.42% 184.44 Delayed Quote.-21.95%
MORPHOSYS AG 5.90% 20.29 Delayed Quote.-42.86%
PEARSON PLC 1.73% 750.6 Delayed Quote.20.32%
SILENCE THERAPEUTICS PLC 27.79% 4.46 Delayed Quote.0.00%
SPARK NETWORKS SE 2.22% 3.23 Delayed Quote.2.87%
TC BIOPHARM (HOLDINGS) PLC 1.36% 0.3729 End-of-day quote.0.00%
TELEFÓNICA, S.A. -2.63% 4.777 Delayed Quote.27.34%
VACCITECH PLC -3.90% 4.43 Delayed Quote.-60.13%
VODAFONE GROUP PLC 0.17% 127.2 Delayed Quote.12.95%
All news about ARGENX SE
06/29US Futures Marginally Higher Ahead of Final Q1 GDP Reading
MT
06/28Stifel Reinstates argenx SE at Buy With $460 Price Target
MT
06/27ARGENX : Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patien..
PU
06/27Argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie..
CI
06/24Argenx Gets Positive CHMP Opinion for Generalized Myasthenia Gravis Drug
MT
06/24Argenx Gets EU Committee's Positive Opinion For Generalized Myasthenia Gravis Treatment
MT
06/24argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie..
GL
06/24Argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie..
AQ
06/17European ADRs Move Lower in Friday Trading
MT
06/15TRANSCRIPT : Argenx SE Presents at Goldman Sachs 43rd Annual Global Healthcare Conference,..
CI
More news
Analyst Recommendations on ARGENX SE
More recommendations
Financials
Sales 2022 170 M 175 M 175 M
Net income 2022 -932 M -954 M -954 M
Net cash 2022 1 518 M 1 556 M 1 556 M
P/E ratio 2022 -19,1x
Yield 2022 -
Capitalization 20 111 M 20 603 M 20 603 M
EV / Sales 2022 109x
EV / Sales 2023 39,6x
Nbr of Employees 650
Free-Float 100%
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 368,10 €
Average target price 372,51 €
Spread / Average Target 1,20%
EPS Revisions
Managers and Directors
Tim van Hauwermeiren Chief Executive Officer
Karl Gubitz Chief Financial Officer
Peter K. M. Verhaeghe Non-Executive Chairman
Hans J. W. de Haard Chief Scientific Officer
Luc Truyen Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ARGENX SE16.75%20 603
GILEAD SCIENCES, INC.-14.14%78 194
VERTEX PHARMACEUTICALS31.59%73 908
REGENERON PHARMACEUTICALS, INC.-5.54%64 277
WUXI APPTEC CO., LTD.-4.30%49 127
BIONTECH SE-37.54%39 133